A Post-marketing Observation Study of the Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic DMARDs Over a Period of 1 Year (QUALITY).
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2015
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms QUALITY
- Sponsors Abbott Laboratories
- 29 May 2012 Actual patient number changed 45 to 46 according to ClinicalTrials.gov.
- 06 Jun 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
- 06 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.